eMed Intelligence
Back to all programs
OncologyHybrid

Prostate & Genitourinary Oncology Review 2027

Genitourinary oncology review covering prostate risk stratification, hormonal therapy and renal cell treatment.

  • Jan 28–29, 2027
  • Demo Riverside Cancer Institute · New York, NY
  • Metropolitan Cancer Education Institute
Prostate CancerGenitourinary OncologyPrecision Oncology
Ask eMed about this program

Learning Objectives

  • Risk-stratify localized prostate cancer accurately
  • Sequence hormonal and targeted therapy
  • Apply current renal cell treatment pathways

Target Audience

  • Medical Oncologists
  • Urologists
  • Radiation Oncologists

Program Highlights

  • Case-based sessions
  • Hybrid attendance
  • Expert panels

Why this program may be relevant to you

32% Match

Based on Dr. Michael Smith’s Cardiology profile — deterministic matching, not AI.

This program is a weak fit for your current profile. It may still be worth a look, but it does not match your specialty or stated preferences closely.

  • Available as Hybrid
  • $520 — within your $750 preference
  • Provides 10 CME credits of the 17 you have remaining

Worth knowing

  • Outside your Cardiology specialty
  • 1371 miles away, outside your preferred 300-mile travel radius